1
|
Johnson K, Delaney JC, Guillard T, Reffuveille F, Varin-Simon J, Li K, Wollacott A, Frapy E, Mong S, Tissire H, Viswanathan K, Touti F, Babcock GJ, Shriver Z, Pentelute BL, Plante O, Skurnik D. Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections. PLoS Pathog 2023; 19:e1011612. [PMID: 37676873 PMCID: PMC10508631 DOI: 10.1371/journal.ppat.1011612] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 09/19/2023] [Accepted: 08/12/2023] [Indexed: 09/09/2023] Open
Abstract
The increase in emerging drug resistant Gram-negative bacterial infections is a global concern. In addition, there is growing recognition that compromising the microbiota through the use of broad-spectrum antibiotics can impact long term patient outcomes. Therefore, there is the need to develop new bactericidal strategies to combat Gram-negative infections that would address these specific issues. In this study, we report and characterize one such approach, an antibody-drug conjugate (ADC) that combines (i) targeting the surface of a specific pathogenic organism through a monoclonal antibody with (ii) the high killing activity of an antimicrobial peptide. We focused on a major pathogenic Gram-negative bacterium associated with antibacterial resistance: Pseudomonas aeruginosa. To target this organism, we designed an ADC by fusing an antimicrobial peptide to the C-terminal end of the VH and/or VL-chain of a monoclonal antibody, VSX, that targets the core of P. aeruginosa lipopolysaccharide. This ADC demonstrates appropriately minimal levels of toxicity against mammalian cells, rapidly kills P. aeruginosa strains, and protects mice from P. aeruginosa lung infection when administered therapeutically. Furthermore, we found that the ADC was synergistic with several classes of antibiotics. This approach described in this study might result in a broadly useful strategy for targeting specific pathogenic microorganisms without further augmenting antibiotic resistance.
Collapse
Affiliation(s)
- Kenneth Johnson
- Visterra, Inc., Waltham, Massachusetts, United States of America
| | - James C. Delaney
- Visterra, Inc., Waltham, Massachusetts, United States of America
| | - Thomas Guillard
- Inserm UMR-S 1250 P3 Cell, Université de Reims-Champagne-Ardenne, Reims, France
| | - Fany Reffuveille
- Inserm UMR-S 1250 P3 Cell, Université de Reims-Champagne-Ardenne, Reims, France
| | | | - Kai Li
- Visterra, Inc., Waltham, Massachusetts, United States of America
| | - Andrew Wollacott
- Visterra, Inc., Waltham, Massachusetts, United States of America
| | - Eric Frapy
- CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France; Faculté de Médecine, University of Paris City, Paris, France
| | - Surin Mong
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
| | - Hamid Tissire
- Visterra, Inc., Waltham, Massachusetts, United States of America
| | | | - Faycal Touti
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
| | | | - Zachary Shriver
- Visterra, Inc., Waltham, Massachusetts, United States of America
| | - Bradley L. Pentelute
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
| | - Obadiah Plante
- Visterra, Inc., Waltham, Massachusetts, United States of America
| | - David Skurnik
- CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France; Faculté de Médecine, University of Paris City, Paris, France
- Department of Clinical Microbiology, Fédération Hospitalo-Universitaire Prématurité (FHU PREMA), Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris City, Paris, France
- Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
| |
Collapse
|
2
|
Wollacott AM, Robinson LN, Ramakrishnan B, Tissire H, Viswanathan K, Shriver Z, Babcock GJ. Structural prediction of antibody-APRIL complexes by computational docking constrained by antigen saturation mutagenesis library data. J Mol Recognit 2019; 32:e2778. [DOI: 10.1002/jmr.2778] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 11/21/2018] [Accepted: 12/06/2018] [Indexed: 12/29/2022]
|
3
|
Touti F, Lautrette G, Johnson KD, Delaney JC, Wollacott A, Tissire H, Viswanathan K, Shriver Z, Mong SK, Mijalis AJ, Plante OJ, Pentelute BL. Antibody-Bactericidal Macrocyclic Peptide Conjugates To Target Gram-Negative Bacteria. Chembiochem 2018; 19:2039-2044. [DOI: 10.1002/cbic.201800295] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Indexed: 12/24/2022]
Affiliation(s)
- Fayçal Touti
- Department of Chemistry; Massachusetts Institute of Technology; Cambridge MA 02139 USA
| | - Guillaume Lautrette
- Department of Chemistry; Massachusetts Institute of Technology; Cambridge MA 02139 USA
| | | | | | | | - Hamid Tissire
- Visterra, Inc.; 275 2nd Avenue 4th Floor Waltham MA 02451 USA
| | | | - Zachary Shriver
- Visterra, Inc.; 275 2nd Avenue 4th Floor Waltham MA 02451 USA
| | - Surin K. Mong
- Department of Chemistry; Massachusetts Institute of Technology; Cambridge MA 02139 USA
| | - Alexander J. Mijalis
- Department of Chemistry; Massachusetts Institute of Technology; Cambridge MA 02139 USA
| | | | - Bradley L. Pentelute
- Department of Chemistry; Massachusetts Institute of Technology; Cambridge MA 02139 USA
| |
Collapse
|
4
|
Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Haserlat S, Abbott S, Tissire H, DiPrima M, Ismail NS, Jiang J, Lerner L, Gyuris J, Weng Z. Abstract 4586: Essential role of fibroblast growth factor receptor 2 (FGFR2) in tumorigenesis of human cancers with activated FGFR2 signaling demonstrated by functional blocking antibodies. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-4586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aberrant activation of fibroblast growth factor receptor 2 (FGFR2) signaling, through overexpression of FGFR2 and/or its ligands, mutations, and receptor amplification have been found in a variety of human tumors. We generated monoclonal antibodies against the extracellular ligand binding domain of FGFR2 to address the role of FGFR2 in tumorigenesis and to explore the potential of FGFR2 as a novel therapeutic target. We identified a broad panel of human cancer cell lines with dysregulated FGFR2 signaling and examined the sensitivity of these human cell lines to monoclonal antibodies specifically targeting FGFR2. These FGFR2 antibodies potently suppressed ligand-induced phosphorylation of FGFR2 and downstream signaling, as well as cell proliferation in vitro. The administration of FGFR2 monoclonal antibodies in mice significantly inhibited the growth of human cancer xenografts harboring activated FGFR2 signaling. Our findings support that dysregulated FGFR2 signaling is one of the critical oncogenic pathways involved in the initiation and/or maintenance of tumors. Cancer patients with aberrantly activated/amplified FGFR2 signaling could potentially benefit from therapeutic intervention with FGFR2-targeting antibodies.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4586. doi:10.1158/1538-7445.AM2011-4586
Collapse
Affiliation(s)
- Ailin Bai
- 1AVEO Pharmaceuticals, Inc., Cambridge, MA
| | | | - Nhi Y. Vo
- 1AVEO Pharmaceuticals, Inc., Cambridge, MA
| | | | | | | | | | | | - Ting Chen
- 1AVEO Pharmaceuticals, Inc., Cambridge, MA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Lacy-Hulbert A, Smith AM, Tissire H, Barry M, Crowley D, Bronson RT, Roes JT, Savill JS, Hynes RO. Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc Natl Acad Sci U S A 2007; 104:15823-8. [PMID: 17895374 PMCID: PMC1994135 DOI: 10.1073/pnas.0707421104] [Citation(s) in RCA: 184] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The gastrointestinal tract is constantly challenged by foreign antigens and commensal bacteria but nonetheless is able to maintain a state of immunological quiescence. Recent advances have highlighted the importance of active suppression by regulatory lymphocytes and immunosuppressive cytokines in controlling mucosal immunity. Failures of these mechanisms contribute to the development of inflammatory bowel disease, but how these regulatory networks are established remains unclear. Here, we demonstrate key roles for alphav integrins in regulation of mucosal immunity. We report that deletion of alphav in the immune system causes severe colitis, autoimmunity, and cancer. Mice lacking immune cell alphav have fewer regulatory T (Treg) cells in the colon and corresponding increases in activated T cells and T cell cytokine production, leading to colitis. Using conditional gene targeting, we demonstrate that this is specifically attributable to loss of alphav from myeloid cells. Furthermore, we show that gut-associated macrophages and dendritic cells fail both to remove apoptotic cells efficiently and to induce Treg cells. Our results identify a vital role for myeloid alphav integrins in generating mucosal Treg cells and emphasize the importance of antigen-presenting cells in establishing immune tolerance.
Collapse
Affiliation(s)
- Adam Lacy-Hulbert
- *Medical Research Council/University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom
- Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139
- To whom correspondence may be addressed at:
Center for Cancer Research, Massachusetts Institute of Technology, 40 Ames Street E17-227, Cambridge, MA 02139. E-mail:
| | - Aileen M. Smith
- *Medical Research Council/University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom
| | - Hamid Tissire
- Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139
| | - Marc Barry
- Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139
| | - Denise Crowley
- Howard Hughes Medical Institute and
- Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139
| | - Roderick T. Bronson
- Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139
- Rodent Histopathology Laboratory, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115; and
| | - Jürgen T. Roes
- Windeyer Institute for Medical Sciences, University College London, 46 Cleveland Street, London W1T 4JF, United Kingdom
| | - John S. Savill
- *Medical Research Council/University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom
| | - Richard O. Hynes
- Howard Hughes Medical Institute and
- Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139
- **To whom correspondence may be addressed. E-mail:
| |
Collapse
|